Arpeggio Bio

[Not Yet Scheduled]
Arpeggio has developed a platform to drug oncogenic transcription factors. Our automated laboratory screens tens of thousands of molecules for changes in TF activity using nascent RNA sequencing. With the world's largest database linking nascent-RNA to small molecules, we use machine learning to identify patterns between molecular structure and transcriptomic impact, unlocking new chemistry for targets like TFs. Our initial pipeline is focused on combating drug resistance in cancer.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Colorado
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
Ferroptosis Inducer
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1